Aimmune Therapeutics Funding & Investors
Brisbane, CA
Aimmune Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing treatments to protect children with food allergies from accidental exposure. Aimmune Therapeutics serves customers in the United States.
aimmune.comTotal Amount Raised: $540,000,000
Aimmune Therapeutics Funding Rounds
Post Ipo Equity
$200,000,000
Post Ipo Equity Investors
Nestlé Health SciencePost Ipo Equity
$98,000,002
Post Ipo Equity Investors
Nestlé Health SciencePost Ipo Equity
$145,000,000
Post Ipo Equity Investors
Nestlé Health ScienceSeries B
$80,000,000
Series B Investors
Foresite CapitalLongitude CapitalFidelity InvestmentsAisling CapitalAdage Capital ManagementRA Capital ManagementIPO
Unknown
Series A
$17,000,000
Series A Investors
Longitude Capital
Funding info provided by Diffbot.